Current Hematologic Malignancy Reports

, Volume 9, Issue 3, pp 203–211

Proton therapy for Hodgkin lymphoma

  • Michael S. Rutenberg
  • Stella Flampouri
  • Bradford S. Hoppe
Lymphomas (J Armitage, Section Editor)

Abstract

Hodgkin lymphoma has gone from an incurable disease to one for which the majority of patients will be cured. Combined chemotherapy and radiotherapy achieves the best disease control rates and results in many long-term survivors. As a result, a majority of long-term Hodgkin lymphoma survivors live to experience severe late treatment-related complications, especially cardiovascular disease and second malignancies. The focus of research and treatment for Hodgkin lymphoma is to maintain the current high rates of disease control while reducing treatment-related morbidity and mortality. Efforts to reduce late treatment complications focus on improvements in both systemic therapies and radiotherapy. Herein we review the basis for the benefits of proton therapy over conventional X-ray therapy. We review outcomes of Hodgkin lymphoma treated with proton therapy, and discuss the ability of protons to reduce radiation dose to organs at risk and the impact on the most significant late complications related to the treatment.

Keywords

Proton therapy Hodgkin lymphoma Outcomes Cardiac Cancer Toxicity Radiotherapy Radiation Particle therapy 

References

Papers of particular interest,published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Peters MV. A study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Radium Ther. 1950;63:299–311.Google Scholar
  3. 3.
    Peters MV. Prophylactic treatment of adjacent areas in Hodgkin's disease. Cancer Res. 1966;26:1232–43.PubMedGoogle Scholar
  4. 4.
    Rosenberg SA, Kaplan HS. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984. Int J Radiat Oncol Biol Phys. 1985;11:5–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Paganetti H. Late Effects from Scattered and Secondary Radiation. In: Pagnetti H, ed(s). Proton Therapy Physics. Boston: Massachusetts General Hospital and Harvard Medical School 2011, 555–70.Google Scholar
  8. 8.
    Kirsch DG, Ebb DH, Hernandez AH, Tarbell NJ. Proton radiotherapy for Hodgkin's disease in the sacrum. Lancet Oncol. 2005;6:532–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Holtzman A, Flampouri S, Li Z, Mendenhall NP, Hoppe BS. Proton therapy in a pediatric patient with stage III Hodgkin lymphoma. Acta Oncol. 2013;52:592–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Hoppe BS, Flampouri S, Li Z, Mendenhall NP. Cardiac sparing with proton therapy in consolidative radiation therapy for Hodgkin lymphoma. Leuk Lymphoma. 2010;51:1559–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Figura NB, Flampouri S, Hopper K, Marcus RB, Mendenhall NP, Hoppe BS. Consolidative Proton Therapy Following High-dose Chemotherapy and Autologous Stem Cell Transplant in an Adolescent with Relapsed Hodgkin Lymphoma. J Adolesc Young Adult Oncol. 2011;1:103–6.CrossRefGoogle Scholar
  12. 12.
    Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, et al.. Involved-Node Proton Therapy in Combined-Modality Therapy for Hodgkin Lymphoma: Results of a Phase II Study. Int J Radiat Oncol Biol Phys. 2014;in press.Google Scholar
  13. 13.
    Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80:199–205.PubMedCrossRefGoogle Scholar
  14. 14.
    Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199–206.PubMedCrossRefGoogle Scholar
  15. 15.
    Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117:1806–16.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van‘t Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99:206–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Henry-Amar M, Hayat M, Meerwaldt JH, Burgers M, Carde P, Somers R, et al. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group. Int J Radiat Oncol Biol Phys. 1990;19:1155–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117:412–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Myrehaug S, Pintilie M, Yun L, Crump M, Tsang RW, Meyer RM, et al. A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood. 2010;116:2237–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28:1308–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–98.PubMedCrossRefGoogle Scholar
  27. 27.
    Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys. 2006;64:218–26.PubMedCrossRefGoogle Scholar
  28. 28.
    Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002;100:1989–96.PubMedCrossRefGoogle Scholar
  29. 29.•
    Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, et al. Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study. Int J Radiat Oncol Biol Phys. 2012;83:260–7. This is an early report of the outcomes of a Phase II trial using proton therapy for stage IA-IIIB Hodgkin disease. It describes the dosimetric benefits with protons compared to IMRT or 3DCRT and relates reduction in dose to improved late treatment-related morbidity and mortality. PubMedCrossRefGoogle Scholar
  30. 30.
    Hoppe BS, Flampouri S, Su Z, Latif N, Dang NH, Lynch J, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84:449–55.PubMedCrossRefGoogle Scholar
  31. 31.•
    Li J, Dabaja B, Reed V, Allen PK, Cai H, Amin MV, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys. 2011;81:167–74. This paper describes ten patients treated using proton therapy for lymphoma (most with Hodgkin lymphoma) and compares the doses to critical structures with proton therapy versus 3DCRT. PubMedCrossRefGoogle Scholar
  32. 32.•
    Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschold P, Petersen PM, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24:2113–8. This paper compares treatment plans using involved-node radiotherapy for 27 patients planned with 3DCRT, VMAT, IMPT, or a mantle field. Estimates are made for the risk of cardiovascular morbidity and mortality, secondary lung and breast cancers, and life years lost as a result of treatment toxicity for each treatment modality. PubMedCrossRefGoogle Scholar
  33. 33.
    Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325:599–605.PubMedCrossRefGoogle Scholar
  34. 34.
    Cella L, Conson M, Caterino M, De Rosa N, Liuzzi R, Picardi M, et al. Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1802–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck Af Rosenschold P, Petersen PM, et al. Doses to head and neck normal tissues for early stage Hodgkin lymphoma after involved node radiotherapy. Radiother Oncol. 2013.Google Scholar
  36. 36.
    Mertens AC, Yasui Y, Liu Y, Stovall M, Hutchinson R, Ginsberg J, et al. Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer. 2002;95:2431–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Venkatramani R, Kamath S, Wong K, Olch AJ, Malvar J, Sposto R, Goodarzian F, Freyer DR, Keens TG, Mascarenhas L. Pulmonary outcomes in patients with Hodgkin lymphoma treated with involved field radiation. Pediatr Blood Cancer. 2014.Google Scholar
  38. 38.
    Jorgensen AY, Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Rosenschold PM, et al. The effect on esophagus after different radiotherapy techniques for early stage Hodgkin's lymphoma. Acta Oncol. 2013;52:1559–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489–97.PubMedCrossRefGoogle Scholar
  40. 40.
    Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465–75.PubMedCrossRefGoogle Scholar
  41. 41.
    van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18:487–97.PubMedGoogle Scholar
  42. 42.
    Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182–92.PubMedCrossRefGoogle Scholar
  43. 43.
    Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27:3901–7.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Henderson TO, Rajaraman P, Stovall M, Constine LS, Olive A, Smith SA, et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012;84:224–30.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Tukenova M, Guibout C, Hawkins M, Quiniou E, Mousannif A, Pacquement H, et al. Radiation therapy and late mortality from second sarcoma, carcinoma, and hematological malignancies after a solid cancer in childhood. Int J Radiat Oncol Biol Phys. 2011;80:339–46.PubMedCrossRefGoogle Scholar
  46. 46.
    Andolino DL, Hoene T, Xiao L, Buchsbaum J, Chang AL. Dosimetric comparison of involved-field three-dimensional conformal photon radiotherapy and breast-sparing proton therapy for the treatment of Hodgkin's lymphoma in female pediatric patients. Int J Radiat Oncol Biol Phys. 2011;81:e667–71.PubMedCrossRefGoogle Scholar
  47. 47.
    Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013;87:46–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Michael S. Rutenberg
    • 1
  • Stella Flampouri
    • 1
  • Bradford S. Hoppe
    • 1
  1. 1.University of Florida Proton Therapy InstituteJacksonvilleUSA

Personalised recommendations